Anavex Life Sciences Corp (AVXL)

[GD]

Street is waiting for the real proof of concept long term efficacy
12 months data, PDD OLE is the starter, like SAVA's 50 patients
9-12 months interim efficacy data, the real show stop for AVXL
is the P2/3 Alzheimer's data next year, but the PDD OLE data,
if positive, will get AVXL's stock rocking because street has
to price in higher chance of both PDD and Alzheimer's final success,
since PDD+Alzheimer's peaks sales potential may be $10+B, we
can see AVXL trading in what ever you think is fair multiples of
peak sales potential, standard multiple is 2.5 to 3 times after
positive PIII results.